Clinical consequences of mast cell heterogeneity

Inflammation Research

Volumn 49, Issue 4, 2000, Pages 147-154

  Forsythe, P ^a   Ennis, M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Heterogeneity; Mast cells

Indexed keywords

AMBROXOL; ANESTHETIC AGENT; ANTIALLERGIC AGENT; BUPRENORPHINE; CONTRAST MEDIUM; MORPHINE; MUCOLYTIC AGENT; MUSCLE RELAXANT AGENT; NEDOCROMIL; OPIATE; PROPOFOL; THEOPHYLLINE; THIOPENTAL; TUBOCURARINE CHLORIDE;

ANAPHYLAXIS; BASOPHIL; CELL ACTIVATION; CELL ACTIVITY; CELL HETEROGENEITY; CELL STIMULATION; HISTAMINE RELEASE; HUMAN; HYPEROSMOLARITY; MAST CELL; MEDIATOR RELEASE; REVIEW;

ANTI-ALLERGIC AGENTS; HUMANS; HYPERSENSITIVITY; MAST CELLS;

EID: 0034117872     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050574     Document Type: Review

References (92)

1. [1] Befus AD, Denburg JA. Basophilic leucocytes: mast cells and basophils. In: Lee GR, Foerster J, Lukens J, editors: Winthrobe's Clinical Hematology. Williams and Wilkins (Publisher) Baltimore. 1998; pp 362-76.
2. [2] Schwartz LB, Huff T. Biology of mast cells and basophils. In: Middleton E (ed): Allergy Principles and Practice. Mosby (Publisher) St. Louis. 1994; pp 135-68.
3. [3] Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34' bone marrow progenitor cells. J Immunol 1991; 146: 1410-5.
4. [4] Kitamura Y, Kasugai T, Nomura S, Matsuda H. Development of mast cells and basophils. In: Foreman JC (ed): Immunopharmacology of mast cells and basophils. Academic Press Ltd. (Publisher) London 1993; pp 5-27.
5. [5] Nilsson G, Miettinen, Ishizaka T, Ashman LK, Irani AM, Schwartz LB. Interleukin-4 inhibits the expression of kit and tryptase during stem cell factor-dependent development of human mast cells from fetal liver cells. Blood 1994; 84: 1519-27.
6. [6] Rottem M, Metcalfe DD. Development and maturation of mast cells and basophils. In: Busse WW, Holgate ST. (eds) Asthma and Rhinitis. Blackwell Scientific Publications (publisher) Boston. 1995; pp 167-181.
7. [7] Hu ZQ, Zenda N, Shimamura T. Down-regulation by IL-4 and up-regulation by IFN-of mast cell induction from mouse spleen cells. J Immunol 1996; 156: 3925-31.
8. [8] Enerbäck L. Mast cells. In: Spicer SS (ed): Histochemistry in pathologic diagnosis Marcel Dekker Inc. (Publishers) New York. 1986; pp 695-728.
9. [9] Galli SJ. Biology of disease: New insights into "The riddle of the mast cells" Microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 1990; 62: 5-33.
10. [10] Barrett KE, Pearce FL. Mast cell heterogenity. In: Foreman JC (ed): Immunopharmacology of mast cells and basophils. Academic Press Ltd. (Publishers) London 1994; pp 29-39.
11. [11] Pearce FL. Functional differences between mast cells from various locations. In: Befus DA, Bienenstock J, Denberg JA (eds): Mast cell differentiation and heterogeneity. Raven Press Ltd (Publishers), New York. 1986; pp 215-22.
12. [12] Nilsson G, Schwartz LB. Mast-cell heterogeneity: structure and mediators. In: Busse WW, Holgate ST (eds): Asthma and Rhinitis. Blackwell Scientific Publications Inc (Publishers) London 1995; pp 195-208.
13. [13] Theoharides TC. The mast cell: A neuroimmunoendocrine master player. Int J Tiss Res 1996; 18: 1-21.
14. [14] McKay D, Bienenstock J. The interaction between mast cells and nerves in the gastrointestinal tract. Immunology Today 1994; 15: 533-8.
15. [15] Marshall JS, Waserman S. Mast cells and the nerves - potential interactions in the context of chronic disease. Clin Exp Allergy 1995; 25: 102-10.
16. [16] Church MK, Okayama Y, Bradding P. Functional mast cell heterogeneity. In: Busse WW, Holgate ST (eds): Asthma and Rhinitis. Blackwell Scientific Publications Inc (Publishers) London 1995; pp 209-20.
17. [17] Heaney LG, Cross LJM, Stanford CF, Ennis M. Substance P induces histamine release from human pulmonary mast cells. Clin Exp Allergy 1995; 25: 179-86.
18. [18] Okayama Y, Benyon RC, Rees PH, Lowman MA, Hillier K, Church MK. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy 1991; 22: 401-9.
19. [19] Pearce FL, Boulos PB, Lau HYA, Liu WL, Tainsh KR. Functional heterogeneity of human mast cells. Int Arch Allergy Appl Immunol 1991; 94: 239-40.
20. [20] Leung KBP, Flint KC, Brostoff J, Hudspith BN, Johnson NMcI, Lau HYA, et al. Effects of sodium cromoglycate on histamine secretion from human lung mast cells. Thorax 1988; 43: 756-61.
21. [21] Okayama Y, Church MK. Comparison of modulatory effect of ketotifin, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int Arch Allergy Immunol 1992; 97: 216-25.
22. 2 agonists: inhibition of TNF α release from human mast cells. J Allergy Clin Immunol 1997; 100: 825-31.
23. [23] Shichijo M, Inagaki N, Naki N, Kimata M, Nakahata T, Serizawa I, et al. The effects of anti-asthma drugs on mediator release from cultured human mast cells. Clin Exp Allergy, 1998; 28: 1228-36.
24. 2 adrenoreceptor agonists on mast cells of rat guinea pig and human. Int Arch Allergy Immunol 1994; 105: 177-80.
25. [25] Marquardt DL, Wasserman SI. Characterization of the rat mast cell beta-adrenergic receptor in resting and stimulated cells by radioligand binding. J Immunol 1982; 31:411-6.
26. [26] Donlon M, Hunt WA, Catravas GN, Kaliner M. A characterization of beta-adrenergic receptors on cellular and perigranular membranes of rat peritoneal mast cells. Life Sci 1982; 31:411-6.
27. [27] Chen X-J, Enerbäck L. Influence of genetic and environmental factors on surface expression and occupancy of IgE receptors and on histamine releasability of mast cells. Int Arch Allergy Immunol. 1995; 106: 241-9.
28. [28] Chen X-J, Enerbäck L. IgE receptors, IgE content and secretory response of mast cells in athymic rats. Immunology 1994; 83: 595-600.
29. [29] Pearce FL, Befus AD, Gauldie J, Bienenstock J. Effects of anti-allergic compounds on histamine secretion by isolated mast cells. J Immunol 1982; 128: 2481-6.
30. [30] Torphy TJ, Livi GP, Balcarek JM, White JR, Chilton FH, Undem BJ. Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma. Adv Sec Messenger and Phosphoprotein Res 1992; 25: 289-305.
31. [31] Louis RE, Radermecker MF. Substance P induced histamine release from human basophils, skin and lung fragments: effect of nedocromil sodium and theophylline. Int Arch Allergy Appl Immunol 1990; 92: 329-33.
32. [32] Banner KH, Moriggi E, Da Ros B, Schioppacassi G, Semeraro C, Page CP. The effect of selective phosphodiesterase 3 and 4 isoenzymes inhibitors and established anti-asthma drugs on inflammatory cell activation. Br J Pharmacol 1996; 119: 1255-61.
33. [33] Gibbs BF, Schmutzler W, Vollrath IB, Brosthardt P, Braam U, Wolff H, et al. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflammation Res 1999; 48: 86-93.
34. [34] Vervloet D, Arnaud A, Senft M, Dor P, Bongrand P, Charpin C, et al. Leukocyte histamine release to suxamethonium in patients with adverse reactions to muscle relaxants. J Allergy Clin Immunol 1985; 75: 338-42.
35. [35] Baldo BA, Fisher MM. Substituted ammonium ions as allergenic determinants in drug allergy. Nature 1983; 306: 262-4.
36. [36] Harle DG, Baldo BA, Coroneos NJ, Fisher MM. Anaphylaxis following administration of papaveretum: Case report. Implication of IgE anti-bodies that react with morphine and codeine, and identification of an allergenic determinant. Anesthesiology 1989; 71: 489-94.
37. [37] Harle DG, Baldo BA, Smal MA, Wajon P, Fisher MM. Detection of thiopentone-reactive IgE antibodies following anaphylactoid reactions during anaesthesia. Clin Allergy 1986; 16:493-8.
38. [38] Watkins J. Markers and mechanisms of anaphylactoid reactions. In: Assem ESK (ed): Allergic Reactions to Anesthetics. Clinical and basic aspects. Basel, Karger, 1992, vol 30, pp 108-29.
39. [39] Weiss ME, Nyhan D, Peng Z, Horrow JC, Lowenstein E, Hirshman C, et al. Association of protamine IgE and IgG antibodies with life threatening reactions to intravenous protamine. N Engl J Med 1989; 320: 886-92.
40. [40] Arroyave CM, Sehatz M, Simon RA. Activation of the complement system by radiographic contrast media: Studies in vivo and in vitro. J Allergy Clin Immunol 1979; 63: 276-80.
41. [41] Cogen FC, Norman ME, Dunsky E, Hirshfeld J, Zweman B. Histamine release and complement changes following injection of contrast media in humans. J Allergy Clin Immunol 1979; 64: 299-303.
42. [42] Schulman ES, Post TJ, Henson PM, Giclas PC. Differential effects of the complement peptides C5a and C5a des Arg on human basophils and lung mast cells. J Clin Invest 1988; 81: 918-26.
43. [43] North FC, Kettelkamp N, Hirshman CA. Comparison of cutaneous and in vitro histamine release by muscle relaxants. Anesthesiology 1987; 66: 543-6.
44. [44] Moss J, Rosow CE, Savarese JJ, Philbin DM, Kniffen KJ. Role of histamine in the hypotensive action of d-tubocurarine in humans. Anesthesiology 1981; 55: 19-25.
45. [45] Erffmeyer JE, Siegle RL, Lieberman P. Anaphylactoid reactions to radiocontrast material. J Allergy Clin Immunol 1985; 75: 401-10.
46. [46] Lieberman P. Anaphylactoid reactions to radiographic contrast material. Immunol Allergy Clin North Am 1992; 3: 649-70.
47. [47] Bush WH, Swanson D. Acute reactions to intravascular contrast media: Types, risk factors, recognition, and specific treatment. AJR 1991; 157: 1153-61.
48. [48] Greenberger PA. Contrast media reactions. J Allergy Clin Immunol 1984; 74: 600-5.
49. [49] Bielory L, Kaliner MA. Anaphylactoid reactions to radiocontrast materials. Int Anesthesiol Clin 1985; 3: 97-118.
50. [50] Simon RA, Schatz M, Stevenson DD, Curry C, Yamamoto F, Plow E, et al. Radiographic contrast media infusions. Measurement of histamine, complement and fibrin split products and correlation with clinical parameters. J Allergy Clin Immunol 1979; 63: 281-8.
51. [51] Kaliner M, Dyer J, Merlin S, Shelton A, Greenhill A, Treadwell G, et al. Increased urine histamine and contrast media reactions. Invest Radiol 1984; 2: 116-8.
52. [52] Ennis M, Lorenz W, Nehring E, Schneider C. In vitro and in vivo studies of radiographic contrast media induced histamine release in pigs. Agents Actions 1991; 33: 26-9.
53. [53] Assem ESK, Bray K. The release of histamine from human basophils by radiological contrast agents. Br J Radiol 1983; 56: 647-52.
54. [54] Salem DN, Findlay SR, Isner JM, Konstan MA, Cohen PF. Comparison of histamine release effects of ionic and non-ionic radiographic contrast media. Am J Med 1986; 80: 382-4.
55. [55] Amon EU, Ennis M, Lorenz W, Schnabel M, Schneider C. Histamine release induced by radiographic contrast media. Comparison between pulmonary and peritoneal mast cells derived from nor-motensive and spontaneously hypertensive rats. Int Arch Allergy Appl Immunol 1990; 92; 203-9.
56. [56] Lorenz W, Ennis M, Doenicke A, Dick W. Perioperative uses of histamine antagonists. J Clin Anesth 1990; 2: 345-60.
57. [57] Stellato C, de Crescenzo G, Patella V, Mastronardi P, Mazzarella B, Marone G. Human basophil/mast cell releasability. XI. Heterogeneity of the effects of contrast media on mediator release. J Allergy Clin Immunol 1996; 97: 838-50.
58. [58] Olin T. Adverse reactions to intravascularly administered contrast media. Acta Radiol 1986; 27: 257-63.
59. [59] Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669-78.
60. [60] Genovese A, Stellato C, Marsella CV, Adt M, Marone G. Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Int Arch Allergy Immunol 1996; 110: 13-22.
61. [61] Ennis M, Forsythe P, Towart R, MacMahon J, Elborn JS. Histamine release from basophils and bronchoalveolar lavage (BAL) cells induced by radiographic contrast media (RCM). Am J Resp Crit Care 1999; 159: A656.
62. [62] Weiss ME, Adkinson NF Jr, Hirshman CA. Evaluation of allergic drug reactions in the perioperative period. Anesthesiology 1989; 71: 483-6.
63. [63] Doenicke A, Lorenz W, Stanworth D, Duka T, Glen GB. Effects of propofol (Diprivan) on histamine release, immunoglobulin levels and activation of complement in healthy volunteers. Postgrad Med J 1985; 61 (Suppl 3): 15-20.
64. [64] Davison TC. Intravenous anesthesia in modern surgery (sodium-penthol-oxygen) Curr Res Anaesth Analg 1943; 22: 52-6.
65. [65] Binkley K, Cheema A, Sussman G, Moudgil G, O'Connor M, Evans S, et al. Generalized allergic reactions during anesthesia. J Allergy Clin Immunol 1992; 89: 768-74.
66. [66] Stellato C, Casolaro V, Ciccarelli A, Mastronardi P, Mazzarella B, Marone G. General anaesthetics induce only histamine release selectively from human mast cells. Br J Anaesth 1991; 67: 751-8.
67. [67] Assem ESK. Anaphylactic anesthesia reactions. Anesthesia 1990; 45: 1032-8.
68. [68] Didier A, Cador D, Bongrand P, Furstoss R, Fourneron P, Senft M, et al. Role of the quaternary ammonium ion determinant in allergy to muscle relaxants. J Allergy Clin Immunol 1982; 79: 578-84.
69. [69] Doenicke A. Pseudo-allergic reactions due to histamine release during intravenous anaesthesia. In: Dukor P (ed): Pseudo-Allergic Reactions. Involvement of Drugs and Chemicals Basel, Karger, 1980, vol 1, pp 224-50.
70. [70] Stellato C, de Paulis A, Crillo R, Mastronardi P, Mazzarella B, Marone G. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 1991; 74: 1078-86.
71. [71] Lowmann MA, Rees PH, Benyon RC, Church MK. Human mast cell heterogeneity: Histamine release from mast cells dispersed from skin, lung adenoids tonsils and colon in response to IgE-dependent and non-immunological stimuli. J Allergy Clin Immunol 1988; 81: 590-7.
72. [72] Tharp MD, Kagey-Sobotka A, Fox CC, Marone G, Lichtenstein LM, Sullivan TJ. Functional heterogeneity of human mast cells from different anatomic sites: In vitro responses to morphine sulphate. J Allergy Clin Immunol 1987; 79: 646-53.
73. [73] Stellato C, Cirillo R, de Paulis A, Casolaro V, Patella V, Mastronardi P, et al. Human basophil/mast cell releasability. IX Heterogeneity of the effects of opioids on mediator release. Anesthesiology 1992; 77: 932-40.
74. [74] Benyon RC, Robinson C, Church MK. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE dependent and non-immunological stimuli. Br J Pharmacol 1989; 97: 898-904.
75. [75] Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman A, Goodman LS, Rall TW, Murad F editors. The Pharmacological Basis of Therapeutics. New York, Pergamon Press 1990, pp 485-521.
76. [76] Conroy MC, Adkinson NF, Lichtenstein LM. Measurement of IgE on human basophils: relation to serum IgE and anti-IgE induced histamine release. J Immunol 1977; 111: 500-11.
77. [77] Assem ESK. Leucocyte bound IgE and cell reactivity in asthma. Allergol et Immunopath 1974; 2: 41-6.
78. [78] Marone G, Giugliano R, Lembo G, Ayala F. Human basophil releasability II Changes in basophil releasability in patients with atopic dermatitis. J Invest Dermatol 1986; 87: 19-23.
79. [79] Marone G. Control mechanisms of mediator release in human basophils and mast cells. Immunol Invest 1988; 17: 707-45.
80. [80] Lichtenstein LM, MacGlashan DW. The concept of basophil releasability. J Allergy Clin Immunol 1986; 77: 291-4.
81. [81] Marquardt DL, Parker CW, Sullivan TJ. Potentiation of mast cell mediator release by adenosine. J Immunol 1978; 120: 871-8.
82. [82] Burt DS, Stanworth DR. The effect of ribose and purine modified adenosine analogues on the secretion of histamine from rat mast cells induced by ionophore A23187. Biochem Pharmacol 1983; 32: 2729-32.
83. 2-purinoreceptor mechanism. Biochem Pharmacol 1984; 33: 3847-52.
84. [84] Leoutsakos A, Pearce FL. The effect of adenosine and its analogues on cyclic AMP changes and histamine secretion from rat peritoneal mast cells stimulated by various ligands. Biochem Pharmacol 1986; 35: 1373-79.
85. [85] Peachell PT, Columbo M, Kagey-Sobotka A, Lichtenstein M, Marone G. Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis 1988; 138: 1143-51.
86. [86] Forsythe P, McGarvey LPA, Heaney LG, MacMahon J, Ennis M. Adenosine induces histamine release from human bronchoalveolar lavage mast cells. Clin Sci 1999; 96: 349-55.
87. [87] Heaney LG, Cross LMJ, Stanford CF, Ennis M. Substance P induces histamine release from human pulmonary mast cells. Clin Exp Allergy 1995; 25: 179-86.
88. [88] Cross LMJ, Heaney LG, Ennis. Histamine release from human bronchoalveolar lavage mast cells by neurokinin A and bradykinin Inflamm Res 1997; 46: 306-9.
89. [89] Forsythe P, McGarvey LPA, Heaney LG, MacMahon J, Ennis M. Sensory neuropeptides induce histamine release from bronchoalveolar lavage cells in both non-asthmatic coughers and cough variant asthmatics. Clin Exp Allergy 2000; 30: 225-32.
90. [90] Flint KC, Leung KBP, Brostoff J, Hudspith BN, Pearce FL, Johnson N Mcl. Bronchoalveolar mast cells in extrinsic asthma: a mechanism for the initiation of antigen specific bronchoconstriction. Br Med J 1985; 291: 923-6.
91. [91] Casolaro V, Galeone D, Giacummo A, Sanduzzi A, Melillo G, Marone G. Human basophil/mast cell releasability. V Functional comparisons of cells obtained from peripheral blood, lung parenchyma, and bronchoalveolar lavage in asthmatics. Am Rev Respir Dis 1989; 139: 1375-82.
92. [92] Saito H, Ebisawa M, Sakaguchi N, Onda T, Iikura Y, Yanagida M, et al. Characterization of cord-blood-derived human mast cells cultured in the presence of steel factor and interleukin-6. Int Arch Allergy Immunol 1995; 107: 63-5.